Highlight

Clinical research 2004, March 1st   The Biopole takes center stage at Investiga   In 2003, the Biopole was already present at the forum Investiga   For the second consecutive year, the Biopole of Poitiers and its companies shall be displaying their assets on the occasion of Investiga, the forum of clinical research. Having taken place just three times, Investiga has devolved into the “must” event of health investigation in France. Organized as an offshoot of the Medec (“Salon de la Médecine”) from March 16th onwards, this veritable crossroads of meetings, exchanges and discussions shall bring together for four days in Paris the many key players of the profession (institutions, laboratories, service providers…). That is reason enough for the Biopole, which is animated by the “communauté d’agglomération de Poitiers” (Greater Poitiers), to undertake the journey for the second consecutive year. “Last year’s experience was highly successful and singularly instructive. At the request of companies, which perceive it as genuinely interesting, we wished to do it again”, confides Bruno Pinzauti, the economic development director of the “CAP”. Poitiers strides ahead, and remains in the forefront The objective of the urban community is clearly set forth – to promote and valorize research and clinical trials in Poitiers. What ought to be known is that the Biopole hosts all stages of the “clinical trials” branch (from phase 1 to phase 4), and is ranked among the top French regions in terms of its capacity pertaining to bioanalysis of drugs: more than 50% of the drugs in France undergoing dosage. All in all, half a dozen companies and four laboratories employing 400 people in the single sector of clinical development (production and sorting out of molecules, bioanalysis of drugs, clinical trials…) are to be found in or near the regional capital: Aster-Cephac, Parexel, Isoclin, Cerep, Bioalternatives, Biocydex, @rtMolecule… This economic breeding ground likewise draws benefit from the proximity of the university hospital and campus with its high-level training programs (advanced “DESS” degrees in clinical trials, pharmaceutical marketing and bio-informatics…), as well as numerous research-based laboratories (CNRS, INSERM and INRA). A salon not to be missed As was the case last year, most of these companies shall show their know-how in Paris at the Biopole stand. “This is a salon in which one has truly got to participate, it concentrates all the activities linked to clinical trials”, confides Hubert Taupe, manager of Isoclin, a national network of doctor investigators. “It allows you to make yourself known and meet future customers. It is also the occasion for the members of the Biopole to get to know each other so as to be able to work together.” These statements are seconded by Fabien Zunino. The director of the young company @rtMolecule, which is specialized in custom synthesis of organic molecules, is very much looking forward to attending the salon for the first time. “Since we went into business, seven months ago, we have been living off word of mouth et thanks to our past knowledge of the pharmaceutical industry. By attending Investiga, which brings together all of our potential customers, we are undertaking are first truly commercial approach.” http://www.biopole-poitiers.org/english The Biopole en masse at Eurobio 2008 Read ...   Water information days (September 23 – September 25) Read ...   The rose and its genetic transformation Read ...   Christian Huyghe aims for “excellence” read...   Creating “medical branches” read...   A neuro-cardio-vascular pole is taking root read...   Valagro on the horticulture market read...   ERM, the winning spin-off read...   GMOs under debate in Poitiers read...   Isabelle Cameleyre, new representative read...   Cystic fibrosis: The molecule of hope read...   Irfaq, a manufacturer of innovations read...   CHU: State-of-the-art quality read...   Soil organic matter under examination read...   Parexel: The Cap provides its support read...   Philippe Michonneau: “The Biopole, fertile soil” read...   Painless monitoring of hepatitis read...   The Biopole structured as an association read...   Futuramat steps up the pace read...   Technova, or life in 3D read...   B Braun burnishes its image read...   Proteomics platform: The CHU strides ahead read...   The three missions of the University Botanical Garden read...   Clinsight in the big leagues read...   Natural energies for an autonomous building read...   Aster-Cephac turns into SGS Cephac read...   The previously unseen heart read...   BIOalternatives diversifies its markets read...   Two Poitiers-based projects awarded read...   IUT pores over biofuels read...   Poitiers, the biotechnology capital read...   PAREXEL wagers on the human factor read...   Saunier and associates wish to diversify read...   Biocydex and BioXtract move forward hand in hand read...   The grass of champions read...   Ianesco steadfastly believes in its future read...   A tumorotheque, what is the purpose it serves? read...   TechnAvOx has turned the corner read...   Larime is aiming for 40 beds in Poitiers read...   Poitiers is out to promote its research read...   A true Biopole milestone read...   A regional cancerology pole in the pipeline for 2007 read...   Nobel prize winners in Poitiers read...   A platform offering numerous advantages read...   @rtMolecule fashions in its own way read...   It’s plastic, it’s fantastic read...   The Poitiers hospital (CHU) stakes its claim read...   BIOalternatives exports its know-how read...   The physiological and computer science engineering program turns 30 read...   The Biopole takes center stage at Investiga read...           Legal mentions